REPL Replimune, Inc.
Price Chart
Executive Summary
Replimune announced alignment with the FDA on a path forward for resubmission of the RP1 BLA for advanced melanoma, with the FDA committing to prioritize review. This is a significant regulatory de-risking event for a clinical-stage biotech with no approved products, transforming the company's outlook.
Actionable Insight
This is a major de-risking event for REPL. The FDA's commitment to prioritize review significantly increases the probability of approval. Traders should watch for the BLA resubmission confirmation and any PDUFA date assignment. Given the prior 120% T+20 move on a neutral filing, this bullish catalyst could drive substantial upside.
Key Facts
- Replimune and FDA aligned on path forward for RP1 BLA resubmission for advanced melanoma
- BLA resubmission expected in coming days; FDA will treat as urgent matter and prioritize review
- RP1 is Replimune's lead product candidate; company has no approved products
- Approximately 8,500 advanced melanoma deaths annually; ~50% of patients fail checkpoint inhibitor therapy
- BLA supported by IGNYTE clinical trial data
Financial Impact
Transformative for a ~$386M market cap clinical-stage biotech; FDA approval would open a multi-hundred-million to billion-dollar market opportunity in advanced melanoma
Risk Factors
- FDA may still issue a Complete Response Letter after review
- Clinical data from IGNYTE trial may not meet approval standards
- Competition from other melanoma therapies could limit commercial potential
- Company has no approved products and limited cash runway
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3303541 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 11, 2026
2d ago
|
Institutional Cluster
| $8.46 awaiting T+5 | awaiting T+5 | — | $8.88 (−4.96%) |
|
May 31, 2026
13d ago
|
Press Release
| $9.00 $9.47 | ▲ +5.22% | ▲ +7.97% | $8.88 (−1.33%) |
|
May 30, 2026
14d ago
|
Press Release
| $9.00 $9.47 | ▲ +5.22% | ▲ +7.97% | $8.88 (−1.33%) |
|
May 29, 2026
15d ago
|
8-K
| $8.69 $9.98 | ▲ +14.84% | ▲ +15.14% | $8.88 (+2.19%) |
|
May 29, 2026
15d ago
|
Press Release
| $8.69 $9.98 | ▲ +14.84% | ▲ +15.14% | $8.88 (+2.19%) |
|
May 20, 2026
23d ago
|
Insider Cluster
| $5.22 $8.69 | ▲ +66.48% | ▲ +64.63% | $8.88 (+70.11%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access